EPH Receptor A5 antibody (Extracellular, N-Term)

Catalog No. ABIN7884937

The Rabbit Polyclonal anti-EPH Receptor A5 antibody is suitable to detect EPH Receptor A5 in samples from Human, Mouse and Rat. It has been validated for WB and IHC.

Quick Overview for EPH Receptor A5 antibody (Extracellular, N-Term) (ABIN7884937)

Target: EPH Receptor A5 (EPHA5)

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EPH Receptor A5 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-EPH Receptor A5 Antibody

Binding Specificity: AA 357-369, Extracellular, N-Term

Purpose: A Rabbit Polyclonal Antibody to EphA5 (Extracellular)

Predicted Reactivity: Rat,human - 12 out of 13 amino acids identical.

Purification: Affinity purified on immobilized antigen.

Immunogen: (C)KSKETSITAEGLK, corresponding to amino acid residues 357 - 369 of mouse EPHA5

Isotype: IgG

Application Details

Application Notes: The optimal concentration should be determined by the user

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for EPH Receptor A5

Target: EPH Receptor A5 (EPHA5)

Alternative Name: EPHA5

Background:

Synonyms: Ephrin type A receptor 5, Brain specific kinase, EPHA5

Description:

EphA5 (EPH Receptor A5) is a member of the Eph receptor tyrosine kinase family, which is the largest group of receptor tyrosine kinases (RTKs) in the human genome. They are divided into two classes-EphA and EphB-based on sequence similarity and ligand binding preferences. EphA receptors (EphA1-A10) typically bind to glycosylphosphatidylinositol (GPI)-anchored ephrin-A ligands, whereas EphB receptors (EphB1-B6) bind to transmembrane ephrin-B ligands.1

EphA5 is predominantly expressed in the developing central nervous system, especially in the cortex, hippocampus, olfactory bulb, and retina. It is critically involved in axon guidance, particularly in the formation of retinotectal and thalamocortical projections, contributing to the correct mapping of neural circuits. In the adult brain, EphA5 influences dendritic spine maturation and synaptic plasticity, which are fundamental for learning and memory.2,3

Eph receptors, including EphA5, are often dysregulated in cancer. EphA5 displays context-dependent roles in cancer, acting as either a tumor suppressor or, in some cases, a tumor promoter, depending on the cellular environment and tumor type. Its role is influenced by its expression pattern, epigenetic status, and interactions with other signaling pathways.4 In certain cancers such as breast and prostate, EphA5 is downregulated, suggesting a tumor-suppressive function, while in others like lung and gastric cancer, EphA5 expression is elevated and correlates with a more aggressive cancer.5,6

All these makes EphA5 a promising target for therapeutic intervention. Indeed, recently an antibody-drug conjugate (ADC) targeting EphA5, has been developed as a highly selective target for directed anticancer therapy.7

Gene ID: 13839

UniProt: Q60629

Pathways: RTK Signaling